Document Detail

Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center.
MedLine Citation:
PMID:  23334068     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Clobazam (CLB) is a 1,5-benzodiazepine, which is known to be effective for treating refractory partial epilepsy. We have evaluated the long-term efficacy and tolerability of CLB as an add-on therapy in patients with Lennox-Gastaut syndrome (LGS).
METHODS: Forty-six patients with LGS who had received CLB add-on therapy were enrolled in this study. We retrospectively reviewed their clinical characteristics, including type of seizures, use of CLB, efficacy, adverse events, and retention rate.
RESULTS: The mean±SD dose of CLB was 0.70±0.37 mg/kg per day (range, 0.16-1.60 mg/kg per day). After 1 month on CLB, 15 patients (32.6%) became seizure-free and 10 patients (21.7%) had 50% or greater seizure reduction. Response to CLB was not significantly associated with age, sex, or etiology (symptomatic or not). Five (10.8%) of 46 patients maintained seizure remission for more than 12 months. Tolerance developed in 48.0% of initial responders, and the 3-year retention rate by the Kaplan-Meier method was 76.6%. Seven patients (15.2%) reported adverse events, including somnolence and behavioral change, but only one discontinued CLB.
CONCLUSIONS: Clobazam add-on therapy was effective and very tolerable in patients with LGS.
Eun Hye Lee; Mi-Sun Yum; Hae-Won Choi; Tae-Sung Ko
Related Documents :
19062248 - A safe, effective, and easy to use warfarin initiation dosing nomogram for post-joint a...
2840378 - Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the ...
7305658 - Greenfield vena caval filter experience: late results in 156 patients.
24649448 - Predictive value of electroencephalography for seizure outcome following corpus calloso...
23423918 - Risk factors for adverse neurocognitive outcomes in school-aged patients after the font...
15852408 - Neurocognitive complications after coronary artery bypass surgery.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  36     ISSN:  1537-162X     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:    2013 Jan-Feb
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-10-17     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / administration & dosage*
Benzodiazepines / administration & dosage*
Child, Preschool
Epilepsy / diagnosis,  drug therapy*
Intellectual Disability / diagnosis,  drug therapy*
Retrospective Studies
Spasms, Infantile / diagnosis,  drug therapy*
Tertiary Care Centers* / trends
Time Factors
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Anticonvulsants; 12794-10-4/Benzodiazepines; 2MRO291B4U/clobazam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Short-term safety of pulse steroid therapy in multiple sclerosis relapses.
Next Document:  Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in ...